#1 Clinical Trials Search in Europe

Explore popular drugs in clinical trials

Check which drugs are currently being frequently studied.

See also our rare diseases glossary and popular diseases list.

Starting by letter

To open the drugs glossary, select a letter from the list below.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All drugs

Most popular drugs

The list below features the most popular substances currently involved in ongoing clinical trials.

Drug Trials
Pembrolizumab 452
Sodium Chloride 414
Carboplatin 340
Cisplatin 282
Paclitaxel 251
Fluorouracil 232
Oxaliplatin 223
Nivolumab 211
Dexamethasone 205
Rituximab 195
Cyclophosphamide 188
Durvalumab 163
Bevacizumab 162
Capecitabine 157
Paracetamol 156
Atezolizumab 147
Docetaxel 128
Prednisone 127
Tocilizumab 125
Prednisolone 122
Gemcitabine 117
Mycophenolate Mofetil 116
Venetoclax 116
Etoposide 115
Pemetrexed 114
Doxorubicin Hydrochloride 110
Infliximab 99
Lenalidomide 98
Semaglutide 92
Ipilimumab 90
Folinic Acid 89
Acetylsalicylic Acid 89
Placebo 85
Paclitaxel Albumin-Bound 84
Cytarabine 79
Daratumumab 79
Calcium Folinate 78
Methotrexate 78
Fludarabine Phosphate 77
Dapagliflozin 73
Letrozole 72
Bortezomib 72
Olaparib 70
Gemcitabine Hydrochloride 69
Obinutuzumab 68
Azacitidine 66
Trastuzumab 65
Lenvatinib 65
Cetuximab 64
Tacrolimus 63
Fulvestrant 63
Irinotecan 61
Methylprednisolone 60
Irinotecan Hydrochloride Trihydrate 59
Temozolomide 59
Cemiplimab 57
Vincristine Sulfate 57
Trastuzumab Deruxtecan 54
Apixaban 52
Enzalutamide 51
Betamethasone Sodium Phosphate 50
Lidocaine Hydrochloride Monohydrate 50
Amoxicillin 49
Dexamethasone Sodium Phosphate 49
Codeine Phosphate 49
Buclizine Hydrochloride 47
Lidocaine Hydrochloride 47
Exemestane 46
Hydrocortisone 46
Empagliflozin 46
Potassium Chloride 45
Ribociclib 45
Anastrozole 45
Adalimumab 45
Pomalidomide 43
Pertuzumab 43
Doxorubicin 43
Clavulanic Acid 42
Tenofovir Alafenamide 42
Oxygen 42
Clopidogrel 42
Rivaroxaban 41
Ibrutinib 41
Ruxolitinib 41
Ropivacaine Hydrochloride 40
Abemaciclib 40
Trimethoprim 40
Bendamustine Hydrochloride 40
Atorvastatin 40
Metformin Hydrochloride 40
Sulfamethoxazole 40
Carfilzomib 39
Propofol 39
Cyclophosphamide Monohydrate 39
Emtricitabine 38
Palbociclib 38
Linezolid 38
Ifosfamide 38
Pemetrexed Disodium 38
Vinorelbine 38

New drugs in trials

The list below features the new substances involved to ongoing clinical trials.

#1 VMX-C001

Clinical trials are studying VMX-C001 in people who take a Factor Xa direct oral anticoagulant and need urgent surgery or another high-bleeding-risk procedure.

2 months ago
#2 LIPASE

Clinical trials are investigating LIPASE, including a new lipase product compared with pancrelipase.

2 months ago
#3 TRIACYLGLYCEROL LIPASE

Clinical trials of TRIACYLGLYCEROL LIPASE are studying a new lipase treatment in adults with exocrine pancreatic insufficiency.

2 months ago
#4 IMA401

Clinical trials are investigating IMA401 in patients with recurrent and/or refractory solid tumors.

2 months ago
#5 ALLERGEN EXTRACTS

Clinical trials are studying BLOMIA TROPICALIS POLYMERIZED EXTRACT as part of a vaccine for dust mite and Blomia tropicalis allergy.

2 months ago
#6 AUR200

Clinical trials are investigating AUR200 in people with generalized myasthenia gravis.

2 months ago

Drugs starting by g

  • 1 

    Gsk4381562A

    ,

    This article discusses the clinical trial of GSK4381562A, a promising drug being studied in combination with other immunotherapies for the treatment of recurrent or metastatic head and neck cancer. The trial aims to evaluate the effectiveness and safety of this new approach compared to existing treatments for patients with PD-L1 positive tumors.

    Related diseases and areas:

  • 1 

    GSK4418959A

    ,

    Clinical trials are studying GSK4418959A in people with dMMR/MSI-H solid tumors, including colorectal cancer. The trials are looking at safety, tolerability, dose selection, and early signs of anti-tumor activity. Some parts test GSK4418959A alone, and others test it with a PD-1 inhibitor.

    Related diseases and areas:

  • 1 

    GSK4524101A

    ,

    Clinical trials are studying GSK4524101A in adults with advanced or metastatic solid tumors, and in a breast cancer expansion group. The research looks at safety, tolerability, how the body handles the treatment, and early signs of anticancer activity, both alone and with niraparib.

    Related diseases and areas:

  • 2 

    Gsk4527226

    ,

    Clinical trials of Gsk4527226 are studying people with early Alzheimer’s disease. These studies look at both safety and how well the treatment may work over time. The trials include a main treatment study and an open-label extension, which follows participants longer after the parent study.

    Related diseases and areas:

  • 1 

    Gsk4532990A

    , ,

    GSK4532990A is being studied in clinical trials for its potential to treat liver diseases, specifically nonalcoholic steatohepatitis (NASH) and alcohol-related liver disease (ALD). These trials aim to assess the drug’s safety, effectiveness, and optimal dosing in patients with various stages of liver fibrosis and impairment. The studies focus on important markers of liver health and disease progression, offering hope for patients with these challenging conditions.

    Related diseases and areas:

  • 1 

    GSK5458514

    ,

    Clinical trials are studying GSK5458514 in men with metastatic castration-resistant prostate cancer (mCRPC). These studies aim to assess safety, tolerability, and the highest dose that can be given, alone or with other anti-cancer agents. The trial is in Phase 1/2 and includes adults with prostate cancer.

    Related diseases and areas:

  • 1 

    GSK5460025A

    ,

    Clinical trials are investigating GSK5460025A in people with dMMR/MSI-H solid tumors, including colorectal cancer. These studies aim to check safety, tolerability, dose, and early signs of anti-cancer activity, both alone and with other cancer treatments. The trial includes adults with specific solid tumors, and one part also looks at colorectal and endometrial cancer.

  • 1 

    GSK5733584

    ,

    Clinical trials are investigating GSK5733584 in people with advanced solid tumors, including gynecological cancers. These studies look at safety, tolerability, and early anticancer activity when GSK5733584 is used with other cancer treatments.

    Related diseases and areas:

  • 5 

    GSK5764227

    , ,

    Clinical trials are studying GSK5764227 in people with advanced cancers, including gastrointestinal tumors, relapsed small cell lung cancer, and other solid tumors. These studies are checking safety, tolerability, and signs of anti-cancer activity in different patient groups and trial phases.

    Related diseases and areas:

  • 1 

    GSK5784283

    ,

    Clinical trials are studying GSK5784283 in adults with uncontrolled asthma. These studies aim to find the right dose and measure effects on airway inflammation and asthma control. The main trial listed here compares GSK5784283 with placebo in adults aged 18 to 75 years.

    Related diseases and areas:

  • 2 

    Gsk6097608

    ,

    Clinical trials are studying Gsk6097608 in people with certain advanced cancers. These trials look at safety and how well Gsk6097608 works in combination with other immunotherapy drugs in first-line treatment for non-small cell lung cancer and head and neck cancer.

    Related diseases and areas:

  • 2 

    Gskvx000000008866

    ,

    This article discusses clinical trials investigating the use of GSKVx000000008866, a novel drug candidate, for the treatment of chronic hepatitis B (CHB). These trials aim to assess the safety, efficacy, and immune response of GSKVx000000008866 alone or in combination with other therapies in patients with CHB who are already on nucleos(t)ide analogue (NA) therapy. The studies explore different dosing regimens and administration methods to determine the most effective approach for managing this persistent viral infection.

    Related diseases and areas:

  • 2 

    Gskvx000000008885

    ,

    Clinical trials are underway to evaluate the safety, efficacy, and immune response of GSKVX000000008885, a novel therapeutic vaccine for chronic hepatitis B (CHB). This vaccine is being tested in combination with other treatments in patients who are already on nucleos(t)ide analogue (NA) therapy. The trials aim to assess the potential of this vaccine to improve outcomes for CHB patients by targeting the hepatitis B virus (HBV) and boosting the immune response against it.

    Related diseases and areas:

  • 2 

    Gskvx000000009151

    ,

    This article discusses clinical trials investigating the use of GSKVX000000009151, a novel therapeutic vaccine, for the treatment of chronic hepatitis B (CHB). The trials aim to evaluate the safety, efficacy, and immune response of this vaccine in combination with other treatments in patients with CHB who are already on nucleos(t)ide analogue (NA) therapy.

    Related diseases and areas:

  • 1 

    Gskvx000000014593

    ,

    This article discusses the clinical trials of GSK’s Herpes Zoster vaccine, known as GSKVx000000014593, in immunocompromised children aged 1-17 who have received kidney transplants. The study aims to assess the safety, reactogenicity, and immune response of this vaccine in this specific patient population. The trials are designed to evaluate the vaccine’s potential in preventing Herpes Zoster (shingles) in these vulnerable children.

    Related diseases and areas:

  • 2 

    Gskvx000000017033

    ,

    This article discusses clinical trials investigating the use of GSKVx000000017033, a novel drug candidate, for the treatment of chronic hepatitis B. The trials aim to assess the safety, efficacy, and immune response of this drug when used alone or in combination with other therapies in patients with chronic hepatitis B who are already on nucleos(t)ide analogue therapy.

    Related diseases and areas:

  • 1 

    GSKVX000000017986

    ,

    Clinical trials are studying GSKVX000000017986 as part of meningococcal vaccine research. These studies look at safety, side effects after vaccination, and immune response in healthy participants. The trial data here focuses on different vaccine formulations and comparisons with other vaccines.

    Related diseases and areas:

  • 5 

    GSKVX000000025896

    ,

    Clinical trials are investigating GSKVX000000025896 in healthy children, mainly to study a chickenpox (varicella) vaccine. These studies look at immune response, safety, and how the vaccine performs compared with marketed vaccines in children aged 12 to 15 months and 4 to 6 years.

    Related diseases and areas:

  • 1 

    GSKVX000000030810

    ,

    Clinical trials are investigating GSKVX000000030810 in people with herpes simplex, including healthy adults and adults with recurrent genital herpes. These studies look at safety, local and whole-body reactions, immune response, and whether the study treatment can reduce herpes episodes. The trials are in Phase 1/2.

    Related diseases and areas:

  • 1 

    GSKVX000000030825

    ,

    Clinical trials are studying GSKVX000000030825 in people with herpes simplex and in healthy adults. These studies look at safety, side effects after each dose, immune response, and whether the treatment can help prevent recurrent genital herpes. The trials include healthy participants aged 18-40 years and participants aged 18-60 years with recurrent genital herpes.

    Related diseases and areas:

  • 1 

    GSKVX000000030918

    ,

    Clinical trials are studying GSKVX000000030918 in people with herpes simplex. These studies look at safety, side effects, immune response, and whether the treatment can help prevent recurrent genital herpes. The trials include healthy adults and adults with recurrent genital herpes.

    Related diseases and areas:

  • 1 

    GSKVX000000034792

    ,

    Clinical trials are studying GSKVX000000034792 in healthy younger and older adults to find and confirm a dose and to assess safety, reactogenicity, and immune response. The trial also compares immune responses after vaccination. These studies help researchers understand how the vaccine performs in prevention of influenza infection.

    Related diseases and areas:

  • 3 

    GSKVX000000034794

    ,

    Clinical trials are investigating GSKVX000000034794 in influenza vaccine studies. These trials look at immune response, safety, and reactogenicity in healthy adults and adults 18 years and older. The studies compare different vaccine versions and measure how well they work and how well they are tolerated.

    Related diseases and areas:

  • 1 

    GSKVX000000034795

    ,

    Clinical trials are investigating GSKVX000000034795 as part of influenza vaccine research in healthy younger and older adults. These studies look at safety, reactogenicity, and immune response, including dose finding and confirmation. The main goal is to see how well the vaccine works in people who do not have influenza infection.

    Related diseases and areas:

  • 1 

    GSKVX000000034796

    , ,

    Clinical trials are investigating GSKVX000000034796 as part of influenza vaccine research in healthy younger and older adults. These studies aim to find and confirm the dose and assess safety, reactogenicity, and immune response. The target population is healthy volunteers taking part in prevention studies for influenza infection.

    Related diseases and areas:

  • 1 

    GSKVX000000034797

    ,

    Clinical trials are investigating GSKVX000000034797 as part of an influenza vaccine study in healthy younger and older adults. The trial is looking at safety, reactogenicity, and immune response, and it compares study vaccine groups with licensed flu vaccines.

    Related diseases and areas:

  • 3 

    GSKVX000000034798

    ,

    Clinical trials are investigating GSKVX000000034798 as part of influenza vaccine studies in healthy adults and adults 18 years and older. These trials look at safety, reactogenicity, and immune response, with some also comparing GSKVX000000034798 to other influenza vaccines. The studies include Phase 1/2 and Phase 2 research.

    Related diseases and areas:

  • 1 

    GSKVX000000039711

    ,

    Clinical trials are investigating GSKVX000000039711 as part of an influenza vaccine study in healthy younger and older adults. The trials aim to assess safety, reactogenicity, and immune response, including dose finding and confirmation.

    Related diseases and areas:

  • 1 

    GSKVX000000040033

    ,

    Clinical trials are investigating GSKVX000000040033 as part of an influenza vaccine study in healthy younger and older adults. The trials aim to find and confirm the dose, and to assess safety, reactogenicity, and immune response. They include healthy volunteers and are designed to compare different vaccine options.

    Related diseases and areas:

  • 1 

    GSKVX000000044501

    ,

    Clinical trials are investigating GSKVX000000044501 in a candidate vaccine study for urinary tract infections. These trials look at safety, immune response, and whether it can help prevent new E. coli UTIs in adults, especially females aged 18 to 64 years.

    Related diseases and areas:

  • 1 

    GSKVX000000046019

    ,

    Clinical trials are investigating GSKVX000000046019 as a candidate vaccine for urinary tract infections (UTIs). The studies aim to check safety, immune response, and whether it can help prevent new E. coli UTIs in adults, especially females aged 18 to 64 years.

    Related diseases and areas:

  • 3 

    GSKVX000000048110

    , ,

    Clinical trials investigating GSKVX000000048110 are studying influenza vaccines in adults, including healthy younger and older adults and adults 18 years and older. These trials look at immune response, safety, and reactogenicity, which means how often side effects happen after vaccination. The studies are in Phase 1/2 and Phase 2.

    Related diseases and areas:

  • 3 

    GSKVX000000048111

    , ,

    Clinical trials are investigating GSKVX000000048111 in studies of influenza vaccines for adults and healthy volunteers. These trials look at immune response, safety, and reactogenicity, which means how often short-term side effects happen after vaccination. The studies include Phase 1/2 and Phase 2 trials in adults 18 years and older.

    Related diseases and areas:

  • 2 

    GSKVX000000070248

    ,

    Clinical trials are investigating GSKVX000000070248 as part of influenza vaccine studies in adults 18 years and older. These trials look at immune response, safety, and reactogenicity, which means how often short-term reactions happen after vaccination. They compare different study vaccine groups and other influenza vaccines.

  • 2 

    GSKVX000000070250

    ,

    Clinical trials are studying GSKVX000000070250 in adults 18 years and older with influenza-related vaccination research. These studies look at immune response, safety, and reactogenicity, which means how often short-term reactions happen after vaccination.

  • 1 

    GSKVX000000070965

    ,

    Clinical trials are studying GSKVX000000070965 in adults 18 years and older. These trials aim to measure immune response, safety, and reactogenicity, which means how often short-term side effects happen after vaccination. The study is for people with influenza, human.

  • 1 

    GT-002

    ,

    Clinical trials are investigating GT-002 in people with schizophrenia spectrum disorders. The TOTEMS study is looking at short-term effects on brain and body response measures, including signs linked to cognitive problems. It aims to compare GT-002 with placebo and oxazepam in adults who meet specific psychosis-related diagnoses.

    Related diseases and areas:

  • 1 

    Gt005

    ,

    Clinical trials are investigating Gt005 in people with geographic atrophy, a form of vision loss linked to age-related macular degeneration. The study data focus on long-term safety, especially in participants who already received Gt005 in earlier Gyroscope studies. The main goal is to see how safe the treatment is over time.

    Related diseases and areas:

  • 1 

    Gtaexs617

    ,

    Clinical trials are investigating Gtaexs617 in people with advanced solid tumors. This article explains what the study is trying to learn, including safety, tolerability, and early anti-tumor activity. It also covers the study phase, who may take part, and the main outcomes being measured.

    Related diseases and areas:

  • 1 

    GUAIACOL

    Clinical trials investigating GUAIACOL are evaluating treatment strategies in people with breast cancer, especially triple negative breast cancer and hormone receptor-low positive/HER2 negative breast cancer. These studies are looking at how well the tested treatments work before surgery and how they affect survival outcomes.

    Related diseases and areas:

  • 2 

    Guanabenz Acetate

    ,

    Clinical trials investigating Guanabenz Acetate are studying its safety and possible benefit in Vanishing White Matter, a rare brain disorder. The trials focus on pediatric patients and children with early childhood onset disease, including a long-term extension study.

    Related diseases and areas:

  • 1 

    Guanfacine

    ,

    Clinical trials investigating Guanfacine are studying its safety and effectiveness in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). The main focus is long-term treatment in patients aged 6 to 17 years, especially when stimulants are not suitable, not tolerated, or not effective.

    Related diseases and areas:

  • 28 

    Guselkumab

    , , , , ,

    Clinical trials are investigating Guselkumab in several immune-mediated diseases, including Crohn’s disease, ulcerative colitis, psoriatic arthritis, psoriasis, and pouchitis. These studies look at how well it works, how safe it is, and how it performs in adults and children, often compared with placebo or other treatments.

    Related diseases and areas:

  • 1 

    GVV858

    ,

    Clinical trials are investigating GVV858 in people with advanced HR+/HER2- breast cancer and other advanced solid tumors. These studies look at safety, tolerability, and the best dose range, and they also test GVV858 alone or with endocrine therapy. The main phase is Phase 1/2.

    Related diseases and areas:

  • 1 

    GXV813

    ,

    Clinical trials are studying GXV813 in hospitalized adults with schizophrenia. These studies aim to assess safety, tolerability, and treatment response, especially in people with an acute episode. The current trial is in Phase 2 and compares GXV813 with placebo.

    Related diseases and areas: